Skip Navigation Links

Eli Lilly | Company Structure Information from ICIS


Eli Lilly is a major pharmaceutical corporation which develops pharmaceutical products. It employs more than 40,360 people worldwide.


Eli Lilly Research Laboratories (LRL) discovers, develops, and clinically evaluates pharmaceutical products and provides ongoing scientific support for marketed products.

 Eli Lilly headquarters (Source: Eli Lilly)

The company has major R&D facilities in seven countries. Its R&D facilities are located in Australia, Belgium, Canada, England, Germany, Japan, Singapore, Spain, and the US. It conducts clinical research in more than 60 countries around the world.


Manufacturing facilities are located in Brazil, China, Egypt, England, France, Germany, Ireland, Italy, Japan, Korea, Mexico, Pakistan, Puerto Rico, Spain and the US. In addition Eli Lilly operates 14 administrative, manufacturing and R&D plants in the US and Puerto Rico.


The company's Elanco Animal Health business markets products worldwide primarily to cattle, poultry and swine producers. With key operations in North America, Europe, the Middle East and Africa, the Asia-Pacific area, and Latin America, Elanco employs approximately 2,000 people and markets its products in more than 100 countries.


Its current product line concentrates on four therapeutic classes: antibacterials, parasiticides, anticoccidials and productivity enhancers.


Download the The ICIS Top 100 Chemical Companies listing here


Company movements


In October 2009, Evonik agreed to acquire Eli Lilly’s Tippecanoe Laboratories manufacturing facility in Lafayette, Indiana. For more on this story please see Evonik expands US synthesis business with Eli Lilly acquisition on ICIS news.

Eli Lilly Strategy & Financial Highlights

Eli Lilly will focus on its ‘innovation-driven’ strategy. The company has built what it states as being ‘one of the most productive R&D organisations in the pharmaceutical industry’. It is currently readying a generation of molecules for the market and restocking its early-stage pipeline. It states that ‘unlike most of its peers’, it does not have any major patent expirations coming up in the next several years. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to also distinguish Eli Lilly from most other major pharmaceutical companies. (Edited from 'Letter to shareholders' - annual report). ICIS also provides you with key financial data listed in table form. More about Eli Lilly Strategy & Financial Highlights


Get news on Eli Lilly plus the latest chemical news, information, data, market movements and analysis in one place with ICIS news


Find details on other chemical companies and suppliers with ICIS search


ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.

Plants and projects:

Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database

Free trial to ICIS
Simon Robinson - The Big Biofuels Blog
For some independent thinking on the burgeoning world of biofuels, click into Simon Robinson's The Big Biofuels Blog here.


INSIGHT: China may see major ethylene shortfall by 2019
"At $50-90/bbl for Brent, UBS estimates the internal rate of return (IRR) for China CTO/MTO projects range from 5-10% – mostly too low to justify inve more

VIDEO: ICIS Special Report: Innovation is key to success


We welcome your feedback. Please feel free to send us your comments on any aspect of this site. Click here to make your comments.